Dyslipidemia – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：184頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Dyslipidemia – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Dyslipidemia - Pipeline Review, H2 2012', provides an overview of the Dyslipidemia therapeutic pipeline. This report provides information on the therapeutic development for Dyslipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dyslipidemia. 'Dyslipidemia - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Dyslipidemia.
- A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dyslipidemia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Dyslipidemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Dyslipidemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Dyslipidemia - Pipeline Review, H2 2012', provides an overview of the Dyslipidemia therapeutic pipeline. This report provides information on the therapeutic development for Dyslipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dyslipidemia. 'Dyslipidemia - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Dyslipidemia.
- A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dyslipidemia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Dyslipidemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Dyslipidemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Dyslipidemia Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Dyslipidemia 10
Dyslipidemia Therapeutics under Development by Companies 12
Dyslipidemia Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Dyslipidemia Therapeutics – Products under Development by Companies 22
Dyslipidemia Therapeutics – Products under Investigation by Universities/Institutes 26
Companies Involved in Dyslipidemia Therapeutics Development 27
Abbott Laboratories 27
Eli Lilly and Company 28
GlaxoSmithKline plc 29
VIRxSYS Corporation 30
Merck & Co., Inc. 31
Euroscreen S.A. 32
Biocon Limited 33
Dr. Reddy's Laboratories Limited 34
Glenmark Pharmaceuticals Ltd. 35
Japan Tobacco Inc. 36
Kowa Company, Ltd. 37
Mitsubishi Tanabe Pharma Corporation 38
Sigma-Tau S.p.A. 39
Zydus Cadila Healthcare Limited 40
GW Pharmaceuticals plc 41
Genfit 42
Ligand Pharmaceuticals Incorporated 43
LifeCycle Pharma A/S 44
IPCA Laboratories Limited 45
Pronova BioPharma ASA 46
Intas Pharmaceuticals Ltd. 47
Jenrin Discovery, Inc. 48
Metabolex, Inc 49
Spherix Incorporated 50
Ache Laboratorios Farmaceuticos S/A 51
Arisaph Pharmaceuticals, Inc. 52
Alder Biopharmaceuticals Inc. 53
Catabasis Pharmaceuticals, Inc. 54
Cerenis Therapeutics SA 55
Essentialis, Inc. 56
Limerick BioPharma, Inc. 57
Esperion Therapeutics, Inc. 58
Connexios Life Sciences Pvt. Ltd. 59
PHARMENA SA 60
Reviva Pharmaceuticals Inc. 61
Dyslipidemia – Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Combination Products 63
Assessment by Route of Administration 64
Assessment by Molecule Type 66
Drug Profiles 69
MK-0524A - Drug Profile 69
JTT705 - Drug Profile 71
GSK256073 - Drug Profile 73
TA-8995 - Drug Profile 74
MBX-8025 - Drug Profile 75
GFT505 - Drug Profile 76
THR-Beta-3196 - Drug Profile 78
DRL 17822 - Drug Profile 79
SPX 8522876 - Drug Profile 81
ARI-3037MO - Drug Profile 82
K-877 - Drug Profile 83
K-877 - Drug Profile 84
pravastatin sodium - Drug Profile 85
Synordia - Drug Profile 86
ZYT1 - Drug Profile 87
JTT-302 - Drug Profile 88
LCP-AtorFen - Drug Profile 89
ZYH7 - Drug Profile 90
ZYH1 - Drug Profile 91
1-Methylnicotinamide - Drug Profile 93
JD-2000 Series - Drug Profile 95
ETC-1002 - Drug Profile 96
JD-5000 Series - Drug Profile 98
JD-6000 Series - Drug Profile 99
HPP593 - Drug Profile 100
VRX1243 - Drug Profile 101
CaPre - Drug Profile 103
Diazoxide Choline Controlled Release - Drug Profile 105
Thyroid Receptor-Beta Agonist - Drug Profile 107
Anacetrapib + Atorvastatin - Drug Profile 108
Anacetrapib + Atorvastatin - Drug Profile 110
LY-2484595 + Atorvastatin - Drug Profile 112
LY2484595 + Simvastatin - Drug Profile 113
LY2484595 + Rosuvastatin - Drug Profile 115
Metabolic Disease Program - Drug Profile 116
GRC 9332 - Drug Profile 117
GW42004 + GW42003 - Drug Profile 118
LY2484595 - Drug Profile 120
CER-627 - Drug Profile 121
CER-628 - Drug Profile 122
CER-002 - Drug Profile 123
HDL Receptor Enhancer - Drug Profile 124
Drug For Dyslipidemia - Drug Profile 125
Rosuvastatin Calcium + Ezetimibe - Drug Profile 126
IN-SUPR-001 - Drug Profile 127
NanoActive Rosuvastatin - Drug Profile 128
SPX-106 + D-Tagatose - Drug Profile 129
PRC-4016 - Drug Profile 131
Drug For Dyslipidemia - Drug Profile 132
ESN-282 - Drug Profile 133
Tamoxifen - Drug Profile 134
Rosuvastatin + Ezetimibe - Drug Profile 135
AHRO-001 - Drug Profile 136
Hydroxychloroquine + Atorvastatin - Drug Profile 137
CAT-2000 - Drug Profile 139
CAT-3000 - Drug Profile 140
AP-5258 - Drug Profile 141
Cardiovascular Program - Drug Profile 142
ALD-306 - Drug Profile 143
KD-026 - Drug Profile 144
RP7000 - Drug Profile 145
4655-K09 - Drug Profile 146
centatin - Drug Profile 147
Dyslipidemia Therapeutics – Drug Profile Updates 148
Dyslipidemia Therapeutics – Discontinued Products 163
Dyslipidemia Therapeutics - Dormant Products 167
Dyslipidemia – Product Development Milestones 172
Featured News & Press Releases 172
Appendix 179
Methodology 179
Coverage 179
Secondary Research 179
Primary Research 179
Expert Panel Validation 179
Contact Us 180
Disclaimer 180
List of Tables
Number of Products Under Development for Dyslipidemia, H2 2012 14
Products under Development for Dyslipidemia – Comparative Analysis, H2 2012 15
Number of Products under Development by Companies, H2 2012 17
Number of Products under Development by Companies, H2 2012 (Contd..1) 18
Number of Products under Development by Companies, H2 2012 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2012 21
Comparative Analysis by Late Stage Development, H2 2012 22
Comparative Analysis by Mid Clinical Stage Development, H2 2012 23
Comparative Analysis by Early Clinical Stage Development, H2 2012 24
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 25
Products under Development by Companies, H2 2012 26
Products under Development by Companies, H2 2012 (Contd..1) 27
Products under Development by Companies, H2 2012 (Contd..2) 28
Products under Development by Companies, H2 2012 (Contd..3) 29
Products under Investigation by Universities/Institutes, H2 2012 30
Abbott Laboratories, H2 2012 31
Eli Lilly and Company, H2 2012 32
GlaxoSmithKline plc, H2 2012 33
VIRxSYS Corporation, H2 2012 34
Merck & Co., Inc., H2 2012 35
Euroscreen S.A., H2 2012 36
Biocon Limited, H2 2012 37
Dr. Reddy's Laboratories Limited, H2 2012 38
Glenmark Pharmaceuticals Ltd., H2 2012 39
Japan Tobacco Inc., H2 2012 40
Kowa Company, Ltd., H2 2012 41
Mitsubishi Tanabe Pharma Corporation, H2 2012 42
Sigma-Tau S.p.A., H2 2012 43
Zydus Cadila Healthcare Limited, H2 2012 44
GW Pharmaceuticals plc, H2 2012 45
Genfit, H2 2012 46
Ligand Pharmaceuticals Incorporated, H2 2012 47
LifeCycle Pharma A/S, H2 2012 48
IPCA Laboratories Limited, H2 2012 49
Pronova BioPharma ASA, H2 2012 50
Intas Pharmaceuticals Ltd., H2 2012 51
Jenrin Discovery, Inc., H2 2012 52
Metabolex, Inc, H2 2012 53
Spherix Incorporated, H2 2012 54
Ache Laboratorios Farmaceuticos S/A, H2 2012 55
Arisaph Pharmaceuticals, Inc., H2 2012 56
Alder Biopharmaceuticals Inc., H2 2012 57
Catabasis Pharmaceuticals, Inc., H2 2012 58
Cerenis Therapeutics SA, H2 2012 59
Essentialis, Inc., H2 2012 60
Limerick BioPharma, Inc., H2 2012 61
Esperion Therapeutics, Inc., H2 2012 62
Connexios Life Sciences Pvt. Ltd., H2 2012 63
PHARMENA SA, H2 2012 64
Reviva Pharmaceuticals Inc., H2 2012 65
Assessment by Monotherapy Products, H2 2012 66
Assessment by Combination Products, H2 2012 67
Assessment by Stage and Route of Administration, H2 2012 69
Assessment by Stage and Molecule Type, H2 2012 72
Dyslipidemia Therapeutics – Drug Profile Updates 152
Dyslipidemia Therapeutics – Discontinued Products 167
Dyslipidemia Therapeutics – Discontinued Products (Contd..1) 168
Dyslipidemia Therapeutics – Discontinued Products (Contd..2) 169
Dyslipidemia Therapeutics – Discontinued Products (Contd..3) 170
Dyslipidemia Therapeutics – Dormant Products 171
Dyslipidemia Therapeutics – Dormant Products (Contd..1) 172
Dyslipidemia Therapeutics – Dormant Products (Contd..2) 173
Dyslipidemia Therapeutics – Dormant Products (Contd..3) 174
Dyslipidemia Therapeutics – Dormant Products (Contd..4) 175
List of Figures
Number of Products under Development for Dyslipidemia, H2 2012 14
Products under Development for Dyslipidemia – Comparative Analysis, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 20
Late Stage Products, H2 2012 22
Mid Clinical Stage Products, H2 2012 23
Early Clinical Stage Products, H2 2012 24
Discovery and Pre-Clinical Stage Products, H2 2012 25
Assessment by Monotherapy Products, H2 2012 66
Assessment by Combination Products, H2 2012 67
Assessment by Route of Administration, H2 2012 68
Assessment by Stage and Route of Administration, H2 2012 69
Assessment by Molecule Type, H2 2012 70
Assessment by Stage and Molecule Type, H2 2012 71
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Dyslipidemia Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Dyslipidemia 10
Dyslipidemia Therapeutics under Development by Companies 12
Dyslipidemia Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Dyslipidemia Therapeutics – Products under Development by Companies 22
Dyslipidemia Therapeutics – Products under Investigation by Universities/Institutes 26
Companies Involved in Dyslipidemia Therapeutics Development 27
Abbott Laboratories 27
Eli Lilly and Company 28
GlaxoSmithKline plc 29
VIRxSYS Corporation 30
Merck & Co., Inc. 31
Euroscreen S.A. 32
Biocon Limited 33
Dr. Reddy's Laboratories Limited 34
Glenmark Pharmaceuticals Ltd. 35
Japan Tobacco Inc. 36
Kowa Company, Ltd. 37
Mitsubishi Tanabe Pharma Corporation 38
Sigma-Tau S.p.A. 39
Zydus Cadila Healthcare Limited 40
GW Pharmaceuticals plc 41
Genfit 42
Ligand Pharmaceuticals Incorporated 43
LifeCycle Pharma A/S 44
IPCA Laboratories Limited 45
Pronova BioPharma ASA 46
Intas Pharmaceuticals Ltd. 47
Jenrin Discovery, Inc. 48
Metabolex, Inc 49
Spherix Incorporated 50
Ache Laboratorios Farmaceuticos S/A 51
Arisaph Pharmaceuticals, Inc. 52
Alder Biopharmaceuticals Inc. 53
Catabasis Pharmaceuticals, Inc. 54
Cerenis Therapeutics SA 55
Essentialis, Inc. 56
Limerick BioPharma, Inc. 57
Esperion Therapeutics, Inc. 58
Connexios Life Sciences Pvt. Ltd. 59
PHARMENA SA 60
Reviva Pharmaceuticals Inc. 61
Dyslipidemia – Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Combination Products 63
Assessment by Route of Administration 64
Assessment by Molecule Type 66
Drug Profiles 69
MK-0524A - Drug Profile 69
JTT705 - Drug Profile 71
GSK256073 - Drug Profile 73
TA-8995 - Drug Profile 74
MBX-8025 - Drug Profile 75
GFT505 - Drug Profile 76
THR-Beta-3196 - Drug Profile 78
DRL 17822 - Drug Profile 79
SPX 8522876 - Drug Profile 81
ARI-3037MO - Drug Profile 82
K-877 - Drug Profile 83
K-877 - Drug Profile 84
pravastatin sodium - Drug Profile 85
Synordia - Drug Profile 86
ZYT1 - Drug Profile 87
JTT-302 - Drug Profile 88
LCP-AtorFen - Drug Profile 89
ZYH7 - Drug Profile 90
ZYH1 - Drug Profile 91
1-Methylnicotinamide - Drug Profile 93
JD-2000 Series - Drug Profile 95
ETC-1002 - Drug Profile 96
JD-5000 Series - Drug Profile 98
JD-6000 Series - Drug Profile 99
HPP593 - Drug Profile 100
VRX1243 - Drug Profile 101
CaPre - Drug Profile 103
Diazoxide Choline Controlled Release - Drug Profile 105
Thyroid Receptor-Beta Agonist - Drug Profile 107
Anacetrapib + Atorvastatin - Drug Profile 108
Anacetrapib + Atorvastatin - Drug Profile 110
LY-2484595 + Atorvastatin - Drug Profile 112
LY2484595 + Simvastatin - Drug Profile 113
LY2484595 + Rosuvastatin - Drug Profile 115
Metabolic Disease Program - Drug Profile 116
GRC 9332 - Drug Profile 117
GW42004 + GW42003 - Drug Profile 118
LY2484595 - Drug Profile 120
CER-627 - Drug Profile 121
CER-628 - Drug Profile 122
CER-002 - Drug Profile 123
HDL Receptor Enhancer - Drug Profile 124
Drug For Dyslipidemia - Drug Profile 125
Rosuvastatin Calcium + Ezetimibe - Drug Profile 126
IN-SUPR-001 - Drug Profile 127
NanoActive Rosuvastatin - Drug Profile 128
SPX-106 + D-Tagatose - Drug Profile 129
PRC-4016 - Drug Profile 131
Drug For Dyslipidemia - Drug Profile 132
ESN-282 - Drug Profile 133
Tamoxifen - Drug Profile 134
Rosuvastatin + Ezetimibe - Drug Profile 135
AHRO-001 - Drug Profile 136
Hydroxychloroquine + Atorvastatin - Drug Profile 137
CAT-2000 - Drug Profile 139
CAT-3000 - Drug Profile 140
AP-5258 - Drug Profile 141
Cardiovascular Program - Drug Profile 142
ALD-306 - Drug Profile 143
KD-026 - Drug Profile 144
RP7000 - Drug Profile 145
4655-K09 - Drug Profile 146
centatin - Drug Profile 147
Dyslipidemia Therapeutics – Drug Profile Updates 148
Dyslipidemia Therapeutics – Discontinued Products 163
Dyslipidemia Therapeutics - Dormant Products 167
Dyslipidemia – Product Development Milestones 172
Featured News & Press Releases 172
Appendix 179
Methodology 179
Coverage 179
Secondary Research 179
Primary Research 179
Expert Panel Validation 179
Contact Us 180
Disclaimer 180
List of Tables
Number of Products Under Development for Dyslipidemia, H2 2012 14
Products under Development for Dyslipidemia – Comparative Analysis, H2 2012 15
Number of Products under Development by Companies, H2 2012 17
Number of Products under Development by Companies, H2 2012 (Contd..1) 18
Number of Products under Development by Companies, H2 2012 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2012 21
Comparative Analysis by Late Stage Development, H2 2012 22
Comparative Analysis by Mid Clinical Stage Development, H2 2012 23
Comparative Analysis by Early Clinical Stage Development, H2 2012 24
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 25
Products under Development by Companies, H2 2012 26
Products under Development by Companies, H2 2012 (Contd..1) 27
Products under Development by Companies, H2 2012 (Contd..2) 28
Products under Development by Companies, H2 2012 (Contd..3) 29
Products under Investigation by Universities/Institutes, H2 2012 30
Abbott Laboratories, H2 2012 31
Eli Lilly and Company, H2 2012 32
GlaxoSmithKline plc, H2 2012 33
VIRxSYS Corporation, H2 2012 34
Merck & Co., Inc., H2 2012 35
Euroscreen S.A., H2 2012 36
Biocon Limited, H2 2012 37
Dr. Reddy's Laboratories Limited, H2 2012 38
Glenmark Pharmaceuticals Ltd., H2 2012 39
Japan Tobacco Inc., H2 2012 40
Kowa Company, Ltd., H2 2012 41
Mitsubishi Tanabe Pharma Corporation, H2 2012 42
Sigma-Tau S.p.A., H2 2012 43
Zydus Cadila Healthcare Limited, H2 2012 44
GW Pharmaceuticals plc, H2 2012 45
Genfit, H2 2012 46
Ligand Pharmaceuticals Incorporated, H2 2012 47
LifeCycle Pharma A/S, H2 2012 48
IPCA Laboratories Limited, H2 2012 49
Pronova BioPharma ASA, H2 2012 50
Intas Pharmaceuticals Ltd., H2 2012 51
Jenrin Discovery, Inc., H2 2012 52
Metabolex, Inc, H2 2012 53
Spherix Incorporated, H2 2012 54
Ache Laboratorios Farmaceuticos S/A, H2 2012 55
Arisaph Pharmaceuticals, Inc., H2 2012 56
Alder Biopharmaceuticals Inc., H2 2012 57
Catabasis Pharmaceuticals, Inc., H2 2012 58
Cerenis Therapeutics SA, H2 2012 59
Essentialis, Inc., H2 2012 60
Limerick BioPharma, Inc., H2 2012 61
Esperion Therapeutics, Inc., H2 2012 62
Connexios Life Sciences Pvt. Ltd., H2 2012 63
PHARMENA SA, H2 2012 64
Reviva Pharmaceuticals Inc., H2 2012 65
Assessment by Monotherapy Products, H2 2012 66
Assessment by Combination Products, H2 2012 67
Assessment by Stage and Route of Administration, H2 2012 69
Assessment by Stage and Molecule Type, H2 2012 72
Dyslipidemia Therapeutics – Drug Profile Updates 152
Dyslipidemia Therapeutics – Discontinued Products 167
Dyslipidemia Therapeutics – Discontinued Products (Contd..1) 168
Dyslipidemia Therapeutics – Discontinued Products (Contd..2) 169
Dyslipidemia Therapeutics – Discontinued Products (Contd..3) 170
Dyslipidemia Therapeutics – Dormant Products 171
Dyslipidemia Therapeutics – Dormant Products (Contd..1) 172
Dyslipidemia Therapeutics – Dormant Products (Contd..2) 173
Dyslipidemia Therapeutics – Dormant Products (Contd..3) 174
Dyslipidemia Therapeutics – Dormant Products (Contd..4) 175
List of Figures
Number of Products under Development for Dyslipidemia, H2 2012 14
Products under Development for Dyslipidemia – Comparative Analysis, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 20
Late Stage Products, H2 2012 22
Mid Clinical Stage Products, H2 2012 23
Early Clinical Stage Products, H2 2012 24
Discovery and Pre-Clinical Stage Products, H2 2012 25
Assessment by Monotherapy Products, H2 2012 66
Assessment by Combination Products, H2 2012 67
Assessment by Route of Administration, H2 2012 68
Assessment by Stage and Route of Administration, H2 2012 69
Assessment by Molecule Type, H2 2012 70
Assessment by Stage and Molecule Type, H2 2012 71
